|
1
|
Couroucée AM, Drouet J, LeMarrec N, Drouet
A and Soulier JP: Blood donors positive for HBsAg and negative for
anti-HBc antibody. Vox Sang. 49:26–33. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raafat A, Yates P, Sellers F, Munro H and
Dow B: Benefit of dynamic over static incubation in the detection
of a low-level HBsAg (chronic carrier) bone donor. Vox Sang.
74:56–58. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y and Wu W: Determination of low
level HBsAg in serum by microparticle enzyme immunoassay.
Hepatobiliary Pancreat Dis Int. 1:262–264. 2002.PubMed/NCBI
|
|
4
|
Satoh K, Iwata-Takakura A, Yoshikawa A,
Gotanda Y, Tanaka T, Yamaguchi T and Mizoguchi H: A new method of
concentrating hepatitis B virus (HBV) DNA and HBV surface antigen:
An application of the method to the detection of occult HBV
infection. Vox Sang. 95:174–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fei CR, Ye AQ and Zhang J: Evaluation of
different methods in determination of low level HBsAg. Zhejiang Da
Xue Xue Bao Yi Xue Ban. 40:436–439. 2011.(In Chinese). PubMed/NCBI
|
|
6
|
Cheng J, Sun CG, Chen Y, Dai YZ, Xu ZL,
Sun GZ and Li XJ: Molecular analysis on chronic hepatitis B
patients with low level HBsAg. Chin J Lab Med. 32:1128–1132.
2009.
|
|
7
|
Cheng J, Sun CG, Chen Y, Xu ZL, Wang GZ,
Sun GZ and Li XJ: Analysis on clinical features and immunity in
chronic hepatitis B virus infected patients with low-level HBsAg.
Afr J Microbiol Res. 4:547–550. 2010.
|
|
8
|
Jeffery-Smith A, Hubb J, Oliver A and Tong
CY: An apparent low level of hepatitis B surface antigen (HBsAg) in
the presence of significant viral replication. J ClinVirol.
77:111–114. 2016.
|
|
9
|
Li JM: Attention to the confirmative tests
of weak reactive samples should be paid in serological testing for
infectious diseases. Chin J Lab Med. 29:577–580. 2006.(In
Chinese).
|
|
10
|
Ozdil B, Cosar AM, Akkiz H, Sandikci MU
and Kece C: Negative correlation between viral load and HBsAg
levels in chronic HBV-infected patients. Arch Virol. 154:1451–1455.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Gascun CF, Fraher M, Crean M, Connell J
and Hall WW: The importance of being earnest: Following up a low
level hepatitis B surface antigen (HBsAg) result. J ClinVirol.
49:79–81. 2010.
|
|
12
|
Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC,
Chen CL, Hsu CA, Kuo SF, Liu CH, Chen PJ, et al: Serum hepatitis B
surface antigen levels help predict disease progression in patients
with low hepatitis B virus loads. Hepatology. 57:441–450. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martinot-Peignoux M, Lapalus M, Asselah T
and Marcellin P: HBsAg quantification: Useful for monitoring
natural history and treatment outcome. Liver Int. 34:97–107. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang G, Lau WY, Zhou WP, Shen F, Pan ZY,
Yuan SX and Wu MC: Prediction of hepatocellular carcinoma
recurrence in patients with low hepatitis B virus DNA levels and
high preoperative hepatitis B surface antigen levels. JAMA Surg.
149:519–527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang XH and Shi XF: Significance of HBsAg
quantification in guiding clinical treatment of chronic hepatitis
B. Zhonghua Gan Zang Bing Za Zhi. 24:317–320. 2016.(In Chinese).
PubMed/NCBI
|
|
16
|
Chen YC: Hepatitis B surface antigen
(HBsAg) levels in the prediction of spontaneous HBsAg
seroclearance. Hepatology. 57:16752013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Yang HI, Lee MH, Jen CL,
Batrla-Utermann R, Lu SN, Wang LY, You SL and Chen CJ: Serum levels
of hepatitis B surface antigen and DNA can predict inactive
carriers with low risk of disease progression. Hepatology.
64:381–389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu L, Liu CY, Wang L and Liu YH: Analysis
of pathological changes and related factors of liver tissue in
patients with low level HBsAg. Zhonghua Gan Zang Bing Za Zhi.
25:526–528. 2017.(In Chinese). PubMed/NCBI
|
|
19
|
Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu
SL, Chang M, Mu CQ, Hu LP, Hua WH, et al: Hepatitis B surface
antigen clearance in inactive hepatitis B surface antigen carriers
treated with peginterferon alfa-2a. World J Hepatol. 8:637–643.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seto WK, Wong DK, Fung J, Hung IF, Fong
DY, Yuen JC, Tong T, Lai CL and Yuen MF: A large case-control study
on the predictability of hepatitis B surface antigen levels three
years before hepatitis B surface antigen seroclearance. Hepatology.
56:812–819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chook JB, Teo WL, Ngeow YF, Tee KK, Ng KP
and Mohamed R: Universal primers for detection and sequencing of
hepatitis B virus genomes across genotypes A to G. J Clin
Microbiol. 53:1831–1835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatazawa Y, Yano Y, Okada R, Tanahashi T,
Hayashi H, Hirano H, Minami A, Kawano Y, Tanaka M, Fukumoto T, et
al: Quasispecies variant of pre-S/S gene in HBV-related
hepatocellular carcinoma with HBs antigen positive and occult
infection. Infect Agent Cancer. 13:72018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tamura K, Stecher G, Peterson D, Filipski
A and Kumar S: MEGA6: Molecular evolutionary genetics analysis
version 6.0. Mol Biol Evol. 30:2725–2729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao H, Liu Y, Chen J, Ding W, Li X, Xu Z,
Yang Y, Chen R, Si L, Xu X, et al: Characterization of hepatitis B
virus (HBV) preS/S gene mutations in blood donors with occult HBV
infection in the baoji area of north china. Transfusion.
57:857–866. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tong S and Revill P: Overview of hepatitis
B viral replication and genetic variability. J Hepatol. 64 (1
Suppl):S4–S16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Norder H, Couroucé AM, Coursaget P,
Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S and
Magnius LO: Genetic diversity of hepatitis B virus strains derived
worldwide: Genotypes, subgenotypes, and HBsAg subtypes.
Intervirology. 47:289–309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chinese Society of Hepatology, Chinese
Medical Association; Chinese Society of Infectious Diseases,
Chinese Medical Association, ; Hou JL and lai W: The guideline of
prevention and treatment for chronic hepatitis B: A 2015 update.
Zhonghua Gan Zang Bing Za Zhi. 23:888–905. 2015.(In Chinese).
PubMed/NCBI
|
|
28
|
WHO Guidelines Approved by the Guidelines
Review Committee, . Guidelines for the prevention-care and
treatment of persons with chronic hepatitis B infection. Geneva:
World Health Organization; 2015
|
|
29
|
Kumar M, Sarin SK, Hissar S, Pande C,
Sakhuja P, Sharma BC, Chauhan R and Bose S: Virologic and
histologic features of chronic hepatitis B virus-infected
asymptomatic patients with persistently normal ALT.
Gastroenterology. 134:1376–1384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin J, Xie J, Liu S, Zhang H, Han L, Lu W,
Shen Q, Xu G, Dong H, Shen J, et al: Association between the
various mutations in viral core promoter region to different stages
of hepatitis B, ranging of asymptomatic carrier state to
hepatocellular carcinoma. Am J Gastroenterol. 106:81–92. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang X, Bi S, Yang W, Wang L, Cui G, Cui
F, Zhang Y, Liu J, Gong X, Chen Y, et al: Evaluation of the impact
of hepatitis B vaccination among children born during 1992–2005 in
china. J Infect Dis. 200:39–47. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mendy ME, McConkey SJ, Sande van der MA,
Crozier S, Kaye S, Jeffries D, Hall AJ and Whittle HC: Changes in
viral load and HBsAg and HBeAg status with age in HBV chronic
carriers in the gambia. Virol J. 16:492008. View Article : Google Scholar
|
|
33
|
Zheng H, Wang FZ, Zhang GM, Miao N, Sun XJ
and Cui FQ: The epidemiological characteristics of HBV
susceptibility in 1–29 years old young people in china in 2006 and
2014: Based on the national sero-survey data analysis. Zhonghua Yu
Fang Yi Xue Za Zhi. 51:581–586. 2017.(In Chinese; Abstract
available in Chinese from the publisher). PubMed/NCBI
|
|
34
|
Cui Y and Jia J: Update on epidemiology of
hepatitis B and C in China. J Gastroenterol Hepatol. 28:7–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Goyal A and Murray JM: The impact of
vaccination and antiviral therapy on hepatitis B and hepatitis D
epidemiology. PLoS One. 9:e1101432014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Y, Wu W, Li LJ, Lou B, Zhang J and
Fan J: Comparison of the results for three automated immunoassay
systems in determining serum HBV markers. Clin Chim Acta.
372:129–133. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Louisirirotchanakul S, Khupulsup K,
Akraekthalin S, Chan KP, Saw S, Aw TC, Cho DH, Shin MG and Lim J:
Comparison of the technical and clinical performance of the
ElecsysHBsAg II assay with the architect, axSym, and advia centaur
HBsAg screening assays. J Med Virol. 82:755–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Krawczyk A, Hintze C, Ackermann J,
Goitowski B, Trippler M, Grüner N, Neumann-Fraune M, Verheyen J and
Fiedler M: Clinical performance of the novel DiaSorin LIAISON((R))
XL murex: HBsAg quant, HCV-Ab, HIV-Ab/Ag assays. J Clin Virol.
59:44–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhong LH, Jiang YM, Lou GQ, Yu XL, Liu H,
Guo JC, Zhu MF and Xun YH: The relationship between serum HBsAg
levels and liver inflammation and fibrosis in patients with chronic
hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.
27:92–94. 2013.(In Chinese). PubMed/NCBI
|
|
40
|
Liu J, Yang HI, Lee MH, Lu SN, Jen CL,
Wang LY, You SL, Iloeje UH and Chen CJ; REVEAL-HBV Study Group, :
Incidence and determinants of spontaneous hepatitis B surface
antigen seroclearance: A community-based follow-up study.
Gastroenterology. 139:474–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Karagoz E, Tanoglu A and Turhan V:
Correlation between hepatitis B surface antigen titers and HBV DNA
levels: What about the parameters affecting this correlation? Saudi
J Gastroenterol. 20:742014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karagoz E, Selek MB, Tanoglu A, Hatipoglu
M, Ulcay A and Turhan V: Comparison of the ElecsysHBsAg II assay
and the architect assay for quantification of hepatitis B surface
antigen in patients with chronic hepatitis B. Infez Med.
24:287–292. 2016.PubMed/NCBI
|
|
43
|
Karra VK, Chowdhury SJ, Ruttala R,
Polipalli SK and Kar P: Clinical significance of quantitative
HBsAgtitres and its correlation with HBV DNA levels in the natural
history of hepatitis B virus infection. J Clin Exp Hepatol.
6:209–215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang T, Dai Y, Lu W, Zhou H, Chen Y, Xu X,
Sun C and Cheng J: An epidemiological survey of HBV infection and
low-level HBsAg in military camps in eastern China. Medicine
(Baltimore). 97:e122012018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zeng DW, Liu YR, Dong J, Zhu YY, Li YB,
Chen J, Zheng Q and Jiang JJ: Serum HBsAg and HBeAg levels are
associated with liver pathological stages in the immune clearance
phase of hepatitis B virus chronic infection. Mol Med Rep.
11:3465–3472. 2015. View Article : Google Scholar : PubMed/NCBI
|
